A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION

This Phase 3, open-label, multicenter study will be conducted to assess the long-term safety, tolerability, and effectiveness of ralinepag as an add-on therapy in subjects with PAH who have participated in the ADVANCE outcomes study [IRB protocol #832052]. The purpose of this clinical research study is to determine: The purpose of this extension clinical research study is to evaluate the effect of the investigational study drug (ralinepag) over a longer period on the following: Your symptoms of PAH. Your ability to exercise (during a walking test). Your heart rate recovery (how quickly your heart rate slows down after a walking test). Your blood test results and study assessments when used with your current treatment for PAH. Your quality of life. Any side effects that you may have during the study.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD
• Age: 99 years or below
• Gender: All